• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1273473 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
) k9 y) Y' C3 V3 \NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
' I& d$ f, c/ d  y+ Author Affiliations( f$ Z, o2 t/ N( x2 \
" M4 y0 J( g6 s7 ^$ t
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ; T& F8 f3 f, F  w
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' e% J! D8 L7 b2 _0 x# G. `6 J
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 f$ X% w$ p* C( ]1 V: x- t  W) \4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
+ H% O" z* X& U, f5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
' o( Z  g4 H" x' N1 u) H6 G6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan / C6 F+ \; [9 o4 W
7Kinki University School of Medicine, Osaka 589-8511, Japan 8 |- \+ S  Q9 [, W- ~. _
8Izumi Municipal Hospital, Osaka 594-0071, Japan 0 @) E4 |7 v6 |; ~8 \
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan - X( n' c# C+ x' ~
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
; @3 w. P$ K5 c" QAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / x, G3 [) ?2 `  J  i% Y
3 r' r2 W& N3 I5 F) i* A8 Z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type ( C  n1 q0 i5 G1 k* O, K

+ X7 `2 w7 R6 {& V8 Q8 A# ?5 jAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
% h. m* R$ _, |4 \) l$ y+ S4 \9 _$ U0 f& p5 l; q6 @% {8 ~& P3 I
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  + W1 g( z! Q" m1 F; K' z5 k7 ]

% C% t0 C9 @" D$ {% OPublished online on: Thursday, December 1, 2011 & z: h: N6 z) m  P6 {
9 y9 Z, \4 q$ ~% E( Q; I
Doi: 10.3892/ol.2011.507
8 h; S4 D  E1 }# I2 E; ]: V6 q9 C1 w; a! v
Pages: 405-410
/ O5 s+ N! N: \3 Q" l9 R9 r  q) C! ~4 r% ^$ z$ z( o
Abstract:& m' H$ `4 J3 x( V. r4 O2 L7 s
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma." }# f  j& @$ ^2 _* `" T

/ R1 t# X. z2 k3 ^  {; F( L
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
8 ]6 P$ U# ?9 q+ @  JF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 , w5 J( R; {0 `7 a
+ Author Affiliations# w( f' B/ G: `8 y4 Y  h
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu + M7 r4 S' h$ I8 s/ Z6 x. T
2Department of Thoracic Surgery, Kyoto University, Kyoto
1 [+ e" j. w; f6 O. [3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan ' d/ S; F2 ?/ c* h8 d) w( l
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
9 j" \0 U! u% ?+ n9 UReceived September 3, 2010.
  @; E  ?2 C( `4 j- `Revision received November 11, 2010.
. s  s* y0 X9 K. O2 t9 `' i7 vAccepted November 17, 2010.
, Y3 x6 f, B/ s3 H6 pAbstract4 {# o$ u" j7 @3 [
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. . y+ g# D2 s# X. E1 F" K
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 6 ^" W% H9 t9 f) c( t
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
4 f) z0 P  R2 r# c6 R' g* ^Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
1 Y& L& c1 c" E  y
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
! w' T+ @& P; @# X" @. f今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
) c) l6 z7 @7 D
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
4 c1 Z3 v' T) s  V5 x: Jhttp://clinicaltrials.gov/ct2/show/NCT01523587
4 e; k* D/ r9 w1 {( `; I8 t, A& y# t* P) w2 f
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
; O9 |+ s' G" x4 o& a: uhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 " s' @/ e; m$ L' c: f6 _
( Z- h% o( i( h' O7 Z) C
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。. f, ^9 B7 j% ]0 o% F
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 ; ~$ ~) `1 J8 y' {8 G* |
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
4 ^8 p, S/ L& O$ M& L& R至今为止,未出 ...

2 U! @- Y5 q8 w/ Q; `没有副作用是第一追求,效果显著是第二追求。0 {4 A: U! P  U1 a+ S) V
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表